rs121918388 — APOB APOB Q2279X

When ApoB Stops Halfway — The Q2279X Truncation and Lifelong Low LDL

Apolipoprotein B-100 (ApoB-100)¹¹ Apolipoprotein B-100 (ApoB-100)
The structural backbone of every LDL and VLDL particle; a 4,536-amino-acid protein that must be assembled in full to form a stable, secretable lipoprotein is the largest secreted protein in the human body. The rs121918388 variant converts codon 2279 of the APOB gene from glutamine (CAG) to a premature stop codon (TAG) on the coding strand — or equivalently, the G>A change seen on the GRCh38 plus strand. The result is a truncated protein approximately 50% the length of full-length ApoB-100, designated apoB-50, that cannot support normal lipoprotein secretion. Heterozygous carriers consistently show LDL cholesterol well below the population norm — a pattern that sharply reduces coronary heart disease risk while introducing a distinct risk of hepatic fat accumulation.

The Mechanism

Full-length ApoB-100 is the non-exchangeable scaffold of LDL and VLDL particles²² LDL and VLDL particles
Low-density and very-low-density lipoproteins — the primary cholesterol-carrying particles in blood; each contains exactly one ApoB-100 molecule assembled in the endoplasmic reticulum of liver hepatocytes. The Q2279X stop codon truncates the protein at roughly the midpoint of its full length, eliminating all C-terminal domains required for stable lipoprotein particle assembly and LDL receptor recognition.

A related intestinal isoform, ApoB-48, spans approximately the first 2,153 amino acids (48% of ApoB-100) and packages dietary fat into chylomicrons for lymphatic absorption. Because the Q2279X truncation occurs at residue 2279 — just downstream of the ApoB-48 editing site — the truncated apoB-50 protein retains the ApoB-48 functional domain intact. In heterozygous carriers, the one intact APOB allele produces full-length ApoB-100 normally, which is sufficient for adequate lipoprotein secretion; LDL cholesterol is reduced but not absent. In the exceedingly rare homozygous state, both alleles produce apoB-50 rather than full-length protein, severely impairing hepatic VLDL secretion and potentially compromising fat-soluble vitamin transport.

The Evidence

Peloso et al. (2019)³³ Peloso et al. (2019) sequenced APOB across 57,973 individuals in 12 case-control studies and identified 37 distinct protein-truncating variants. Heterozygous carriers showed 43 mg/dL lower LDL-C, a 30% reduction in triglycerides, and a 72% lower risk for coronary heart disease⁴⁴ 72% lower risk for coronary heart disease
OR 0.28; 95% CI 0.12–0.64; P=0.002. This magnitude of LDL reduction, sustained over a lifetime, is comparable to or exceeding the benefit of high-intensity statin therapy.

The tradeoff is hepatic steatosis. Ferri et al. (2025)⁵⁵ Ferri et al. (2025) showed that APOB loss-of-function carriers have lower atherosclerotic cardiovascular disease risk but increased chronic liver disease risk — particularly in the presence of diabetes and obesity. Hepatic ultrasound studies find steatosis in up to 73% of carriers in clinical referral cohorts, though the prevalence in unselected population carriers is lower. About 5–10% of heterozygous carriers develop nonalcoholic steatohepatitis (NASH), and progression to cirrhosis is documented but rare.

GeneReviews (Burnett et al., 2021)⁶⁶ GeneReviews (Burnett et al., 2021) defines the surveillance standard: fasting lipid panel and liver function tests every 1–2 years in heterozygous carriers; hepatic ultrasound every 3 years if transaminases are persistently elevated. Serum fat-soluble vitamin levels (A, D, E, K) are checked only when gastrointestinal symptoms suggest impaired chylomicron formation — a clinical scenario unusual in heterozygotes but essential to recognize.

rs121918388 is exceptionally rare in population databases; the A allele appears at a frequency of approximately 0.00001 globally in the PAGE study (1 carrier in ~78,000 individuals), with no homozygotes identified in any large sequencing effort. This rarity is typical of severely truncating APOB alleles, which are under negative selection in the homozygous state.

Practical Actions

Heterozygous carriers (AG genotype) rarely require any pharmacological intervention. The naturally low LDL is cardioprotective; it is the hepatic fat deposition and the minority risk of NASH that require periodic surveillance. Knowing about this variant is particularly valuable before starting any LDL-lowering medication — the already-reduced baseline changes the dosing calculus and makes standard lipid targets potentially inappropriate.

Interactions

APOB rs121918388 heterozygosity creates a chronic low-LDL state that compounds with PCSK9 loss-of-function variants (rs11591147, rs562556): carriers of both an APOB truncation and a PCSK9 LOF variant may have near-absent LDL-C, making ApoB protein measurement (rather than calculated LDL-C) the preferred lipid biomarker. Within the APOB gene, other truncating variants — including the frameshift rs121918384 (p.Val1856fs) — produce the same FHBL1 phenotype; compound heterozygosity for two different APOB loss-of-function alleles produces biallelic disease equivalent to the homozygous state.